Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs.

Morrato EH, Libby AM, Orton HD, Degruy FV 3rd, Brent DA, Allen R, Valuck RJ.

Am J Psychiatry. 2008 Jan;165(1):42-50. Epub 2007 Nov 6.

PMID:
17986680
2.

Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs.

Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ.

Am J Psychiatry. 2007 Aug;164(8):1198-205.

PMID:
17671282
3.

Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ.

Am J Psychiatry. 2007 Jun;164(6):884-91.

PMID:
17541047
4.

Persisting decline in depression treatment after FDA warnings.

Libby AM, Orton HD, Valuck RJ.

Arch Gen Psychiatry. 2009 Jun;66(6):633-9. doi: 10.1001/archgenpsychiatry.2009.46.

PMID:
19487628
5.

Pediatric prescribing practices and the FDA Black-box warning on antidepressants.

Cheung A, Sacks D, Dewa CS, Pong J, Levitt A.

J Dev Behav Pediatr. 2008 Jun;29(3):213-5. doi: 10.1097/DBP.0b013e31817bd7c9.

PMID:
18550990
7.

Antidepressants use in pediatric populations.

Gören JL.

Expert Opin Drug Saf. 2008 May;7(3):223-5. doi: 10.1517/14740338.7.3.223 .

PMID:
18462180
8.

Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.

Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephenson H, Schatzberg AF.

Arch Gen Psychiatry. 2007 Apr;64(4):466-72.

PMID:
17404123
9.

Psychopharmacology. FDA weighs suicide risk in children on antidepressants.

Holden C.

Science. 2004 Feb 6;303(5659):745. No abstract available.

PMID:
14764841
10.

National trends in prescribing antidepressants before and after an FDA advisory on suicidality risk in youths.

Chen SY, Toh S.

Psychiatr Serv. 2011 Jul;62(7):727-33. doi: 10.1176/ps.62.7.pss6207_0727.

PMID:
21724784
11.

[SSRIs (selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children].

Tandt H, Audenaert K, van Heeringen C.

Tijdschr Psychiatr. 2009;51(6):387-93. Review. Dutch.

12.

Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets.

Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ.

Am J Psychiatry. 2007 Jul;164(7):1044-9.

PMID:
17606656
13.

The selective serotonin reuptake inhibitors controversy in the treatment of depression in children.

Weller EB, Tucker S, Weller RA.

Curr Psychiatry Rep. 2005 Apr;7(2):87-90.

PMID:
15802083
14.

Antidepressants and suicidality: the basis of controversies.

Marcinko D.

Psychiatr Danub. 2007 Sep;19(3):238-40.

PMID:
17914327
15.

A black-box warning for antidepressants in children?

Newman TB.

N Engl J Med. 2004 Oct 14;351(16):1595-8. No abstract available.

PMID:
15483275
16.

Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression.

Valluri S, Zito JM, Safer DJ, Zuckerman IH, Mullins CD, Korelitz JJ.

Med Care. 2010 Nov;48(11):947-54. doi: 10.1097/MLR.0b013e3181ef9d2b.

PMID:
20856141
17.

Improving outcome in pediatric depression.

Emslie GJ.

Am J Psychiatry. 2008 Jan;165(1):1-3. doi: 10.1176/appi.ajp.2007.07101647. No abstract available.

PMID:
18178747
18.

Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns?

Busch SH, Frank RG, Leslie DL, Martin A, Rosenheck RA, Martin EG, Barry CL.

Psychiatr Serv. 2010 Jan;61(1):11-6. doi: 10.1176/appi.ps.61.1.11.

19.

Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ.

Am J Psychiatry. 2007 Sep;164(9):1356-63.

PMID:
17728420
20.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.

Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

J Ment Health Policy Econ. 2002 Mar;5(1):3-19.

PMID:
12529566

Supplemental Content

Support Center